Biotech selling an inhaled treprostinil therapy (Yutrepia) for pulmonary hypertension, competing with United Therapeutics.
Biotech selling an inhaled treprostinil therapy (Yutrepia) for pulmonary hypertension, competing with United Therapeutics.
Yutrepia reached the market in 2025 after FDA approval, so the company is moving from development to selling its own drug. Sales run through specialty pharmacies, which supply patients with this class of drug. United Therapeutics, which sells rival treprostinil products, has contested its patents.
Moat: narrow (IP / patents, process know-how). Proprietary dry-powder particle-engineering technology differentiates its inhaled treprostinil from liquid rivals.
Headquarters: Morrisville, North Carolina, United States · Founded: 2004 · Employees: 216
Size Liquidia (LQDA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.08B, the 1165th largest of 3,085 United States companies the cockpit tracks. Shares closed at $56.40 on 18 Nov 2026.
Performance Over six months the shares fell 8.7%, against +10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 798.4% over the last twelve months (peer median +11.3%); the operating margin is 47.1% (peer median 20.6%).
Valuation It trades at 13.8× forward earnings against a peer median of 28.7× (4th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +192%, so the hurdle is -187 pp: the price already allows for a slowdown.
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $622M | $158M | $14.0M | $17.5M | $15.9M |
| Revenue growth | — | +1,031% | -20% | +10% | — |
| Gross profit | $576M | $144M | $6.82M | $13.4M | $11.3M |
| EBITDA | $295M | -$49.8M | -$119M | -$71.2M | -$34.8M |
| Net income | -$94.2M | -$68.9M | -$128M | -$78.5M | -$41.0M |
| Free cash flow | $291M | -$40.0M | -$98.4M | -$42.9M | -$29.2M |
| Capital expenditure | $33.0M | $4.34M | $4.95M | $1.29M | $592,000 |
| Total debt | $169M | $198M | $120M | $3.50M | $24.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Liquidia LQDA | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% |
| United Therapeutics UTHR | $24.6B | +2% | +2% | 44% | 23.9× | 0.3% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Insmed INSM | $26.3B | +3% | +240% | -42% | n/a | n/a |
| Gossamer Bio GOSS | n/a | -34% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LQDA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +55.2% | -1.2% | highest of 21 |
| 6-month return | -8.7% | +10.6% | 7th lowest of 21 |
| Distance from 52-week high | -39.8% | -21.1% | 6th lowest of 21 |
| Revenue growth (TTM) | +798.4% | +11.3% | highest of 19 |
| Operating margin | 47.1% | 20.6% | highest of 19 |
| Forward P/E | 13.8× | 28.7× | 4th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | 7.3% | 8th least demanding of 17 |
| Growth delivered (Del g) | +192.5% | +12.5% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -187.4 pp | -2.6 pp | 2nd least demanding of 17 |
| EV / EBITDA | 16.5× | 22.8× | 3rd cheapest of 11 |
| Net debt / EBITDA | -0.8× | -0.7× | 6th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |